Christoph May

1.3k total citations
25 papers, 998 citations indexed

About

Christoph May is a scholar working on Transplantation, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Christoph May has authored 25 papers receiving a total of 998 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Transplantation, 9 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Christoph May's work include Renal Transplantation Outcomes and Treatments (10 papers), Neurological Complications and Syndromes (6 papers) and Polyomavirus and related diseases (4 papers). Christoph May is often cited by papers focused on Renal Transplantation Outcomes and Treatments (10 papers), Neurological Complications and Syndromes (6 papers) and Polyomavirus and related diseases (4 papers). Christoph May collaborates with scholars based in Germany, Switzerland and United States. Christoph May's co-authors include Klemens Budde, Claudia Sommerer, Wolfgang Arns, Kai‐Uwe Eckardt, Martin Büchert, Nicholas Obermüller, Harald Gschaidmeier, Gerd Walz, Marwan Mannaa and Jens Gaedeke and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Christoph May

25 papers receiving 976 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christoph May Germany	12	398	325	295	207	177	25	998
Ryan C. Hedgepeth United States	12	549 1.4×	506 1.6×	83 0.3×	224 1.1×	7 0.0×	18	1.1k
Bonnie Mitchell United States	14	70 0.2×	155 0.5×	72 0.2×	81 0.4×	20 0.1×	28	804
E. Schmid Germany	12	53 0.1×	147 0.5×	64 0.2×	267 1.3×	33 0.2×	14	948
Mir Reza Bekheirnia United States	15	195 0.5×	274 0.8×	53 0.2×	64 0.3×	9 0.1×	29	804
Claudia Izzi Italy	19	341 0.9×	565 1.7×	32 0.1×	204 1.0×	8 0.0×	52	1.3k
Gerald S. Spear United States	15	187 0.5×	244 0.8×	32 0.1×	107 0.5×	9 0.1×	38	693
Maria Sandovici Netherlands	22	57 0.1×	214 0.7×	58 0.2×	731 3.5×	27 0.2×	64	1.2k
Noriaki Tokuda Japan	16	57 0.1×	203 0.6×	125 0.4×	279 1.3×	9 0.1×	60	798
Chi Lai United States	21	26 0.1×	165 0.5×	180 0.6×	173 0.8×	59 0.3×	41	1.1k
Ching-Fang Wu Taiwan	8	36 0.1×	348 1.1×	70 0.2×	170 0.8×	9 0.1×	11	814

Countries citing papers authored by Christoph May

Since Specialization

Citations

This map shows the geographic impact of Christoph May's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christoph May with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christoph May more than expected).

Fields of papers citing papers by Christoph May

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christoph May. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christoph May. The network helps show where Christoph May may publish in the future.

Co-authorship network of co-authors of Christoph May

This figure shows the co-authorship network connecting the top 25 collaborators of Christoph May. A scholar is included among the top collaborators of Christoph May based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christoph May. Christoph May is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Budde, Klemens, Martin Zeier, Oliver Witzke, et al.. (2017). Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial. Nephrology Dialysis Transplantation. 32(6). 1060–1070. 29 indexed citations

Watz, Henrik, et al.. (2016). Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD — A randomised, multicentre, crossover trial. Pulmonary Pharmacology & Therapeutics. 42. 13–20. 3 indexed citations

Boy, Sandra, Jörg Marienhagen, Gerhard Schuierer, et al.. (2016). Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study. PLoS ONE. 11(12). e0168215–e0168215. 16 indexed citations

Deuse, T., Christoph Bara, Markus J. Barten, et al.. (2015). The MANDELA study: A multicenter, randomized, open-label, parallel group trial to refine the use of everolimus after heart transplantation. Contemporary Clinical Trials. 45(Pt B). 356–363. 10 indexed citations

Budde, Klemens, Timo Räth, Claudia Sommerer, et al.. (2014). Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clinical Nephrology. 83 (2015)(1). 11–21. 30 indexed citations

Lehner, Frank, Claudia Sommerer, Wolfgang Arns, et al.. (2014). Post Hoc Subgroup Analysis of ZEUS: Outcome On Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion From a Calcineurin Inhibitor to an Everolimus Based Regimen.. Transplantation. 98. 613–613. 1 indexed citations

Arns, Wolfgang, Claudia Sommerer, Petra Glander, et al.. (2013). A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year. Clinical Nephrology. 79(6). 421–431. 6 indexed citations

Jacobi, Johannes, Maike Büttner, Klaus Korn, et al.. (2013). BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition. BMC Nephrology. 14(1). 207–207. 47 indexed citations

Räth, Timo, Klemens Budde, Claudia Sommerer, et al.. (2012). Renal Function of an Everolimus Based Therapy after Calcineurin Inhibitor Withdrawal in Maintenance Renal Transplant Recipients: 3 Year Data of the APOLLO Trial. Transplantation. 94(10S). 994–994. 2 indexed citations

10.

Budde, Klemens, Frank Lehner, Claudia Sommerer, et al.. (2012). Conversion From Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3-Year Results From the Randomized ZEUS Study. American Journal of Transplantation. 12(6). 1528–1540. 70 indexed citations

11.

Hadji, Peyman, M. Ziller, Tobias Maurer, et al.. (2012). The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer. Journal of bone oncology. 1(3). 88–94. 2 indexed citations

12.

Pavel, Marianne, Bertram Wiedenmann, Jaume Capdevila, et al.. (2012). RAMSETE: A single-arm, multicenter, single-stage phase II trial of RAD001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in Europe.. Journal of Clinical Oncology. 30(15_suppl). 4122–4122. 14 indexed citations

13.

Schalke, Berthold, Sandra Boy, Hans‐Stefan Hofmann, et al.. (2012). Neoadjuvant treatment of primary inoperable or local recurrent thymoma with octreotide LAR to improve tumor resectability.. Journal of Clinical Oncology. 30(15_suppl). 7105–7105. 1 indexed citations

14.

Escudier, Bernard, Sergio Bracarda, Pablo Maroto, et al.. (2012). Open-Label Phase II Trial of First-Line Everolimus Monotherapy in Patients with Advanced Papillary Renal Cell Carcinoma: Raptor Interim Analysis. Annals of Oncology. 23. ix264–ix264. 4 indexed citations

15.

Arns, Wolfgang, Claudia Sommerer, Oliver Witzke, et al.. (2012). Efficacy and Safety of Three Different Treatment Regimens in de Novo Renal Transplant Patients: Results of the HERAKLES Trial. Transplantation. 94(10S). 995–995. 4 indexed citations

16.

Huober, Jens, Peter A. Fasching, M. Barsoum, et al.. (2011). Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial. The Breast. 21(1). 27–33. 171 indexed citations

17.

Walz, Gerd, Klemens Budde, Marwan Mannaa, et al.. (2010). Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine. 363(9). 830–840. 433 indexed citations

18.

Lein, Michael, Kurt Miller, Manfred Wirth, et al.. (2009). Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. The Prostate. 69(6). 624–632. 32 indexed citations

19.

Engel, Ulrike, S. Gottschalk, L. Niehaus, et al.. (2000). Cystic lesions of the pineal region - MRI and pathology. Neuroradiology. 42(6). 399–402. 68 indexed citations

20.

May, Christoph, et al.. (1999). Evaluation of shunt function in hydrocephalic patients with the radionuclide 99m Tc-pertechnetate. Child s Nervous System. 15(5). 239–244. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact